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Abstract
Identifying the downstream effects of disease-associated single nucleotide polymorphisms (SNPs)
is challenging: the causal gene is often unknown or it is unclear how the SNP affects the causal
gene, making it difficult to design experiments that reveal functional consequences. To help
overcome this problem, we performed the largest expression quantitative trait locus (eQTL) meta-
analysis so far reported in non-transformed peripheral blood samples of 5,311 individuals, with
replication in 2,775 individuals. We identified and replicated trans-eQTLs for 233 SNPs
(reflecting 103 independent loci) that were previously associated with complex traits at genome-
wide significance. Although we did not study specific patient cohorts, we identified trait-
associated SNPs that affect multiple trans-genes that are known to be markedly altered in patients:
for example, systemic lupus erythematosus (SLE) SNP rs49170141 altered C1QB and five type 1
interferon response genes, both hallmarks of SLE2-4. Subsequent ChIP-seq data analysis on these
trans-genes implicated transcription factor IKZF1 as the causal gene at this locus, with
DeepSAGE RNA-sequencing revealing that rs4917014 strongly alters 3’ UTR levels of IKZF1.
Variants associated with cholesterol metabolism and type 1 diabetes showed similar phenomena,
indicating that large-scale eQTL mapping provides insight into the downstream effects of many
trait-associated variants.
Genome-wide association studies (GWAS) have identified thousands of variants that are
associated with complex traits and diseases. However, because most variants and their
proxies are non-coding, it is generally difficult to identify the causal genes. Recently, several
eQTL-mapping studies5-8 have now shown that the majority of disease-predisposing
variants actually affect gene expression levels of nearby genes (i.e. cis-eQTLs). A few
recent studies have also identified trans-eQTLs5,9-13, revealing the downstream
consequences of some variants. However, the total number of reported trans-eQTLs is fairly
low, mainly due to the severe burden of multiple testing. To improve statistical power, we
performed an eQTL meta-analysis in 5,311 peripheral blood samples, from seven studies
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using Illumina gene expression arrays (EGCUT14, InCHIANTI15, Rotterdam Study16,
Fehrmann5, HVH17-19, SHIP-TREND20, and DILGOM21) and replication analysis in
another 2,775 samples. We aimed to ascertain to what extent SNPs affect genes in cis and
trans and whether eQTL mapping in peripheral blood could reveal important downstream
pathways that may be putative drivers of disease processes.
Our genome-wide analysis identified cis-eQTLs for 44% of all tested genes (6,418 genes at
probe-level false discovery rate (FDR) < 0.05 and 4,690 genes with more stringent
Bonferroni multiple testing correction, Table 1, Supplementary Table 1, Supplementary
Figures 1-3). Our trans-eQTL analysis focused on 4,542 SNPs that have been implicated in
complex disease or traits (derived from the “Catalog of Published GWAS”). In the discovery
dataset, we detected trans-eQTLs at FDR < 0.05 for 1,513 significant trans-eQTLs that
include 346 unique SNPs (8% of all tested SNPs, Table 1, Supplementary Table 2,
Supplementary Figure 4 and 5). These SNPs affect the expression of 430 different genes (a
more stringent Bonferroni correction revealed 643 significant trans-eQTLs, including 200
unique SNPs and 223 different genes).
We used stringent procedures for trans-eQTL detection (Supplementary methods), and
various benchmarks to ensure reliability: for 26 trans-eQTL genes the eQTL SNP affected
multiple probes within these genes (Supplementary Table 3), always with consistent allelic
directions, suggesting that our probe filtering procedure was effective in preventing false-
positive trans-eQTLs. We observed uniform directionality for 90% of the tested trans-
eQTLs across all studies within our discovery meta-analysis (Supplementary Figure 5). We
did not find evidence that the eQTLs were driven by differences in age or blood cell-counts
between individuals (Supplementary Results and Supplementary Table 4, Supplementary
Figure 6). However, we cannot exclude this possibility entirely because FACS analyses on
individual cell-types had not been conducted.
To ensure reproducibility of the trans-eQTLs of our current meta-analysis, we performed
various analyses. We replicated previously reported blood trans-eQTLs5 (Supplementary
Table 5, Supplementary Results and Supplementary Figure 7) and replicated trans-eQTLs
from our discovery meta-analysis in two independent studies of peripheral blood gene
expression (52% in KORA F422, N = 740 samples and 79% in BSGS23, N = 862 samples,
FDR < 0.05, Supplementary Figure 8). Irrespective of significance, 91% and 93% of all
1,513 significant trans-eQTL SNP-probe combinations showed consistent allelic direction in
these replication cohorts as compared to the discovery analysis. A meta-analysis of these
two replication studies improved replication rates: 89% of the 1,513 trans-eQTLs were
significantly replicated (FDR < 0.05), 99.7% of which showed a consistent allelic direction.
Irrespective of significance, 97% of the trans-eQTLs showed a consistent allelic direction in
this replication meta-analysis (Supplementary Figure 8). We found that some trans-eQTLs
could also be detected in three cell-type-specific datasets (283 monocyte samples9, 282 B-
cell samples9 and 608 HapMap lymphoblastoid cell-line (LCL) samples24; Supplementary
Figures 9 and 10). Despite the different tissue of these three studies, we were still able to
significantly replicate 7%, 4% and 2% of the trans-eQTLs (FDR < 0.05), respectively. As
95% of the trans-eQTL SNPs explained less than 3% of the total expression variance
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(Supplementary Figure 11), we lack statistical power to replicate most trans-eQTLs in these
smaller replication cohorts.
We subsequently confined further analyses to 2,082 different SNPs that have been found
associated with complex traits at genome-wide significant levels (‘trait-associated SNPs’,
reported P < 5 × 10-8, out of 4,542 unique SNPs that we tested). These 2,082 SNPs showed a
significantly higher number of transeQTL effects as compared to the 2,460 tested SNPs with
reported disease associations at lower significance levels (P = 8 × 10-22, Supplementary
methods and results, Supplementary Figure 12): 254 of these 2,082 SNPs show a trans-
eQTL effect in the discovery analysis (reflecting 1,340 SNP-probe combinations, of which
we significantly replicated 1,201 SNP-probe combinations, reflecting 233 different SNPs
and 103 independent loci in blood). For 671 out of these 1,340 trans-eQTLs (50%) the trait-
associated SNP was either the strongest trans-eQTL SNP within the locus (or in strong LD
with the strongest trans-eQTL SNP) or unlinked to the strongest trans-eQTL SNP
(Supplementary results and Supplementary Table 6). We observed that the 2,082 trait-
associated SNPs were six times more likely to cause trans-eQTL effects than randomly
selected SNPs (matched for distance to gene and allele frequency, P = 5.6 × 10-49,
Supplementary methods and results, Supplementary Figure 13). SNPs, associated with
(auto)immune or hematological traits were twice as likely to cause trans-eQTLs, as
compared to other trait-associated SNPs (P = 5 × 10-25, Supplementary methods and
results). We observed that trait-associated SNPs that also cause trans-eQTLs more often
affect the expression levels of nearby transcription factors in cis, as compared to trait-
associated SNPs that do not affect genes in trans (Fisher's exact P = 0.032; Supplementary
results), suggesting that some of the trans-eQTLs arise due to altered cis gene expression
levels of nearby transcription factors.
We also examined genomic SNP properties of the trans-eQTLs: these SNPs (and their
perfect proxies based on data from the 1000 Genomes Project25,26) are significantly
enriched (Fisher's exact P < 0.05) for mapping within miRNA binding sites (Figure 1A).
They map to regions showing strong enrichment (fold-change > 2.5) of histone enhancer
signals in K562 (myeloid) and GM12878 (lymphoid) cell-lines (Figure 1B), when compared
to six non-blood cell-lines. This myeloid and lymphoid enhancer enrichment supports the
validity of our blood-derived trans-eQTLs. These enrichment results suggest tissue
specificity, which is supported by our inability to replicate a strong trans-eQTL that was
previously identified in adipose tissue for SNP rs473170213 that is associated with both type
2 diabetes and lipid levels.
These trans-eQTLs can provide insight into the pathogenesis of disease. Although RNA
microarray studies have revealed dysregulated pathways for many complex diseases, it is
often unclear what comes first: whether the associated SNPs first cause defects in the
pathways whose dysregulation ultimately leads to disease, or whether the SNPs first cause
disease that then perturbs these pathways. One example is SLE, an auto-immune disease
resulting in inflammation and tissue damage. It is known that SLE patients show markedly
increased type 1 interferon (IFN-α) levels, increased expression of IFN-α response
genes4,27,28 and decreased complement C1q expression. We observed that four common
SLE associated variants do indeed affect IFN-α response genes in cis (IRF5, IRF7, TAP2
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and PSMB9;Supplementary Table 1). However, as most SLE-associated SNPs do not map
near complement or IFN-α response genes, we assessed whether these SNPs might affect
complement or IFN-α response genes in trans. This was the case for rs4917014, for which
the SLE risk allele (rs4917014*T, showing genome-wide significance in Asian populations
and nominal significance in European populations1,24) not only increased expression of five
different IFN-α response genes (HERC5, IFI6, IFIT1, MX1 and TNFRSF21; Figure 2), but
also decreased expression of three different probes in CLEC10A. In addition, we observed a
nominal significant association of rs4917014*T with decreased expression of C1QB (P = 5.2
x 10-6, FDR 0.28), a subunit of the first component of complement C1q, which has an
established protective role in lupus. The complete deletion of C1q practically assures the
development of SLE29,30. CLEC10A and CLEC4C belong to the C-type lectin family, which
also includes mannose-binding lectins (MBL). While, to our knowledge, CLEC10A and
CLEC4C have not been studied in the context of SLE, the role of MBL is similar to C1q and
is a risk factor for the development of autoimmunity in both humans and mice3. The
rs4917014 trans-eQTLs were well replicated in the peripheral blood and monocyte
replication datasets and reinforce the role of altered IFN-α mediated pathway, C-type lectin
and C1q gene expression in SLE. In addition, people who do not have SLE, but who carry
the rs497014*T risk allele already show these pathway alterations, which indicates these
affected pathways are not solely a consequence of SLE, but could well precede SLE onset.
We next investigated the underlying mechanisms of the effects exerted by rs4917014.
IKZF1 is the only gene residing within the rs4917014 locus. Being a transcription factor
(Ikaros family zinc finger 1), cis-regulatory effects of rs4917014 on IKZF1, that would
translate in altered IKZF1 protein levels, could provide a working mechanism for the
detected trans-eQTLs. However, since our meta-analysis initially did not show a cis-eQTL
on the Illumina probe for IKZF1 that is located near the 5’ untranslated region (UTR) of
IKZF1, we investigated the 3’-UTR by using DeepSAGE next-generation RNA-sequencing
data of 94 peripheral blood samples. The variant rs4917014*T strongly increased the 3’-
UTR expression levels of IKZF1 (Spearman correlation = 0.45, P = 6.29 x 10-6, Zhernakova
et al, submitted). We then used ChIP-seq data from the ENCODE-project31 and observed
significantly increased IKZF1 protein binding to the genomic DNA locations where the
upregulated trans-eQTL genes map (Wilcoxon P-value = 0.046), compared to IKZF1
binding to all other genic DNA. We also observed increased IKZF1 binding to the other
SLE cis-genes outside of the IKZF1 locus (Wilcoxon P-value = 4.3 × 10-4), thereby
confirming the importance of IKZF1 in SLE. IKZF1 is important for other phenotypes as
well: another, unlinked intronic variant within IKZF1, rs12718597, is associated with mean
corpuscular volume (MCV) 32 and affects the 5’ end of IKZF1 in cis. As IKZF1 knock-out
mice show abnormal erythropoiesis33, this suggests a causal role for IKZF1 in MCV as well.
However, although rs12718597*A increases expression of 31 trans-genes and decreases
expression of another 19 trans-genes, none of the SLE trans-genes overlap the MCV trans-
genes. The latter are mainly involved in hemoglobin metabolism and do not show an
increased IKZF1-binding signal, Wilcoxon P = 0.35. In summary, these results indicate that
IKZF1 has multiple functions and that different SNPs near IKZF1 elicit function-specific
effects.
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We identified other trans-eQTLs showing similar phenomena: we observed that rs174546
(located in the 3’-UTR of FADS1, and associated with metabolic syndrome34, LDL and total
cholesterol levels35,36) affects C11orf10, FADS1 and FADS2 in cis and LDLR in trans.
LDLR encodes the LDL receptor and contains common variants that are also associated with
lipid levels36 (Figure 3). LDLR gene expression levelscorrelated negatively (P < 3.0 × 10-4)
with total, HDL and LDL cholesterol levels in the tested cohorts (Rotterdam Study and
EGCUT, Supplementary Table 7), indicating that peripheral blood is a useful tissue for
gaining downstream insight into the effects of lipid SNPs.
For 21 different complex traits, we found that at least two unlinked variants that are
associated with these diseases, affected exactly the same gene in trans. When taking an
equally sized, but permuted list of trans-eQTLs we would on average find only one complex
trait where two unlinked SNPs affected the same gene in trans (Figure 4, Supplementary
Table 8, Online methods). Although most of these traits are hematological (e.g. mean
platelet volume or serum iron levels) we also observed this convergence for blood pressure,
celiac disease, multiple sclerosis, and type 1 diabetes (T1D). rs3184504 (located in an exon
of SH2B3) and its near-perfect proxy rs653178 (located in an intronic region of ATXN2 on
chromosome 12) are associated with several auto-immune diseases including T1D37,38, T1D
auto-antibodies37,38, celiac disease8,39, hyperthyroidism40, vitiligo41, rheumatoid arthritis39
and other complex traits such as blood pressure42,43, chronic kidney disease44, and
eosinophil counts45.
We observed a cis-eQTL on SH2B3 (FDR < 0.05) and fourteen trans-eQTL genes (FDR <
0.05, Figure 5), all highly expressed in neutrophils. Since these trans-eQTLs could
potentially appear due to the known effect of rs3184504 on differences in cell-count
proportions45, we correlated trans-gene expression levels with cell counts in two cohorts
(the Rotterdam Study and EGCUT) but did not observe significant correlations
(Supplementary Table 6). These fourteen trans-eQTLs describe different biological
functions: T1D disease risk allele rs3184504*T decreases expression levels of nine genes,
most of which are involved in toll-like receptor signaling46 (C12orf75, FOS, IDS, IL8,
LOC338758, NALP12, PPP1R15A, S100A10 and TAGAP) and increases expression of five
genes involved in interferon-γ response (GBP2, GBP4, STAT1, UBE2L6 and UPP1). We
observed that another T1D risk allele, rs4788084*C37,38 on chromosome 16, increases
expression of GBP4 and STAT1 as well (Figure 5), revealing how different T1D risk alleles
converge: they both cause an increase of interferon-γ response gene expression.
In summary, our eQTL meta-analysis revealed and replicated downstream effects for 233
trait-associated SNPs. We have highlighted only a few here and shown that trans-eQTL
mapping in blood for lipid and immune-mediated disease variants yields downstream insight
which is biologically meaningful. Our results on IKZF1 show that the two unlinked SLE and
MCV variants near this gene give strikingly different yet biologically meaningful trans-
regulatory effects. Future, larger-scale trans-eQTL analysis in blood will likely uncover
many more of these regulatory relationships.
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Online methods
Study populations
We performed a whole-genome eQTL meta-analysis of 5,311 samples from peripheral
blood, divided over a total of nine datasets from seven cohorts, including EGCUT14 (N =
891), InCHIANTI15 (N = 611), Rotterdam Study16 (N = 762), Fehrmann5 (N = 1,240 on the
Illumina HT12v3 platform and N = 229 on the Illumina H8v2 platform), HVH17-19 (N = 43
on the Illumina HT12v3 platform and N = 63 on the Illumina HT12v4 platform) SHIP-
TREND20 (N = 963), and DILGOM21 (N = 509). Gene expression data for each dataset was
obtained using either PAXGene (Becton Dickinson) or Tempus tubes (Life Technologies),
followed by hybridization to Illumina whole-genome Expression BeadChips (HT12v3,
HT12v4 or H8v2 arrays). The gene expression platforms were harmonized by matching
probe sequences across the different platforms. Mappings for these sequences were obtained
by mapping the sequences against the human genome build 36 (Ensembl build 54, Hg18)
using BLAT, BWA and SOAPv2 sequence alignment programs. Highly stringent alignment
criteria were used to ensure that probes map unequivocally to one single genomic position.
Genotype data was acquired using different genotyping platforms, and harmonized by
imputation, using the HapMap247 Central European population as a reference. Each dataset
was individually checked for sample mix-ups using MixupMapper48. For a full description
of the individual datasets, results of the sample mix-up analysis, specifics on the gene
expression platforms and probe mapping procedure and filtering, see Supplementary
methods.
Gene expression normalization
Gene expression data was quantile-normalized to the median distribution, and subsequently
log2 transformed. The probe and sample means were centered to zero. Gene expression data
was then corrected for possible population structure by removal of four multi-dimensional
scaling components using linear regression. We reasoned earlier that normalized gene-
expression data still contains large amounts of non-genetic variation5. After population
stratification correction, principal component analysis (PCA) was therefore performed on
the sample correlation matrix. We performed a separate QTL analysis for each principal
component (PC), to ascertain whether genetic variants could be detected that affect the PC.
If we found an effect on the PC, we did not correct the expression data for these
components, to ensure we would not unintentionally remove genetic effects from the
expression data. Significance of these associations was established by controlling the false
discovery rate (FDR), testing each association against a null-distribution created by
repeating the analysis 100 times (permuting the sample labels for each iteration49). PCs that
did not show significance at the FDR threshold of 0.0 were removed from the gene
expression data by linear regression. In all but two very small datasets, the first 40 PCs were
removed (excluding those components per cohort that showed a QTL effect). We observed
that the removal of these 40 components revealed the highest number of eQTLs in each
dataset. Although PC correction may remove some eQTL effects, we observed that the
majority (95% when removing 35 PCs and 90% when removing 40 PCs) of trans-eQTL
effects was independent of the number of PCs removed (Supplementary Figure 14).
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eQTL mapping
After normalization of the data, we performed both cis- and trans-eQTL mapping. eQTLs
were deemed cis-eQTLs, when the distance between the SNP chromosomal position and the
probe midpoint was less than 250 kilobases (kb), while eQTLs with a distance greater than
five megabases (mb) were defined as trans-eQTLs. Only SNPs with a minor allele-
frequency (MAF) > 0.05 and a Hardy-Weinberg equilibrium p-value > 0.001 were included
in the analyses. Since most cohorts had generated the gene expression data using the
HT12v3 platform, we chose to only include probes that were present on this platform. We
only tested SNP-probe pairs when the SNP passed quality control in at least three cohorts.
Furthermore, in order to reduce issues with respect to computational time and multiple
testing, we confined our transeQTL analysis to those SNPs present in the “Catalog of
Published GWAS” (http://www.genome.gov/gwastudies/, accessed July 16th, 2011). We
reasoned that for genes with strong cis-eQTL effects, the cis-eQTL effect may obscure the
detectability of trans-eQTL. Therefore, we used linear regression to remove cis-eQTL
effects prior to trans-eQTL mapping and observed a 12% increase in the number of detected
trans-eQTLs (Supplementary Figure 15). For each cohort, eQTLs were mapped using a
Spearman's rank correlation on the imputed genotype dosage values. We used a weighted Z-
method for subsequent meta-analysis50. To get a realistic null-distribution, we permuted the
sample identifiers labels of the expression data and repeated this analysis ten times
(Supplementary Figure 16). In each permutation the sample labels were permuted. We then
corrected for multiple testing by controlling the FDR at 0.05, by testing each p-value in the
real data against a null-distribution created from the permuted datasets49 (see Supplementary
methods). It has been suggested that false-positive eQTL effects can arise due to
polymorphisms in the probe sequences51,52. Therefore, we tested whether a significant cis-
eQTL SNP was in LD (r2 > 0.2) with any SNP in the cis-probe sequence, using the Western
European subpopulations of the 1000 genomes project25 (2011-05-21 release, 286
individuals, excluding Finnish individuals) as a reference. If we observed this to be the case
the respective cis-eQTLs were removed. Furthermore, for each trans-eQTL we investigated
whether portions of the probe sequence could map in the vicinity of the trans-eQTL SNP
(which in fact would imply a cis-eQTL, rather than a trans-eQTL effect). Therefore, we
tried to map the trans-eQTL probe sequences, using very permissive settings, within a 5 Mb
window of the trans-eQTL SNP. SNP-probe combinations where the probe mapped with at
least 15 bp within the 5 Mb window, were deemed false-positive and removed from further
analysis. After this filtering we recalculated the FDR for both the cis- and trans-eQTL
results.
Trans-eQTL replication
Replication of the trans-eQTL results was carried out in five independent datasets from four
cohorts, including data obtained from lymphoblastoid cell lines (HapMap3, N = 60424), B-
cells and monocytes (Oxford9, N = 282 and N = 283, respectively), and whole peripheral
blood (KORA F422, N = 740, and BSGS23, N = 862). All the cohorts applied the same
methodology as used in the discovery phase to normalize the gene expression data, check for
sample mix-ups and perform trans-eQTL mapping, including 10 permutations in order to
establish the FDR threshold at 0.05. Finally, we performed a sample-size weighted Z-score
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meta-analysis on the two peripheral blood replication cohorts (KORA and BSGS). Further
details on these datasets can be found in the Supplementary methods.
Enhancer enrichment and functional annotation
To determine whether the significant trans-eQTL SNPs were enriched for functional regions
on the genome, we annotated the trans-eQTL SNPs using SNPInfo53, SNPNexus54,55, and
HaploReg56, which integrate multiple data sources (such as ENCODE project data31,
Ensembl57, and several micro-RNA databases). We limited these analyses to those trans-
eQTL SNPs that were previously shown to be associated with complex traits at genome-
wide significance levels (‘trait associated SNPs’, reported P < 5 × 10-8). These SNPs were
subsequently pruned (using PLINK's --clump command, using an r2 < 0.2). We used the
permuted trans-eQTL data to get realistic null-distributions for each of these tools: we
selected equally sized sets of unlinked SNPs (r2 < 0.2 in the Western-European
subpopulations of the 1000 genomes project25, 2011-05-21 release, 286 individuals,
excluding Finnish individuals) that showed the highest significance in the permuted data,
ensuring that only trait-associated SNPs are included in the null-distribution, as it is known
that trait-associated SNPs in general already have different functional properties than
randomly selected SNPs58 (e.g. trait-associated SNPs typically map in closer proximity to
genes than random SNPs). We also ensured that none of the SNPs in the null-distribution
were affecting genes in trans, or were linked to those SNPs (r2 < 0.2 in 1000 genomes). We
then identified perfect proxies (r2 = 1.0 in 1000 genomes). For SNPInfo and SNPNexus, we
calculated the enrichment for each functional category using a Fisher's exact test. We
determined the enhancer enrichment in nine different cell-types using HaploReg, where we
averaged the enhancer enrichment over the ten permutations.
Convergence analysis
We determined which unlinked trait-associated SNPs show eQTL effects on exactly the
same gene: per trait, we analyzed the SNPs that are known to be associated with this trait
and assessed whether any unlinked SNP pair (r2 < 0.2, distance between SNPs > 5Mb)
showed a cis- and/or trans-eQTL effect on exactly the same gene, as previously described5.
To determine whether the number of traits for which we observed this phenomenon was
higher than expected by chance, we re-ran this analysis 20 times, each time using a different
set of permuted trans-eQTLs, equal in size to the non-permuted set of trans-eQTLs.
SLE IKZF1 ENCODE ChIP-seq Analysis
We used IKZF1 ChIP-seq signal data obtained from the ENCODE-project31 (IKZF1 ChIP-
seq data acquired and processed by UCSC, ENCODE March 2012 Freeze). For every human
gene we determined the average signal (corrected for gene size), corrected for GC-content
bias, and performed a Wilcoxon Mann-Whitney test to see whether the upregulated genes
(MX1, TNFRSF21, IFIT1/LIPA, HERC5, CLEC4C, IFI6) showed a higher ChIP-seq signal
compared to all other human genes.
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Data availability
We have made a browser available for all significant trans-eQTL and cis-eQTL at http://
www.genenetwork.nl/bloodeqtlbrowser. This browser also provides all trans-eQTLs that we
detected at a somewhat less stringent false discovery rate of 0.5, to enable more in-depth
post-hoc analyses.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Trans-eQTL SNPs are enriched for functional elements
We investigated whether the trans-eQTL SNPs are enriched for certain functional elements.
We used the online tools SNPInfo, SNPNexus, and HaploReg that rely upon data from,
amongst others, the ENCODE project. (a) We observed that trans-eQTL SNPs are enriched
for mapping within miRNA binding sites (b) trans-eQTL SNPs show strong enrichment (as
annotated using HaploReg) for enhancer regions that are present in K562 (myeloid) and
GM12878 (lymphoid) cell-lines (error bars represent one standard deviation).
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Figure 2. Independent trans-eQTL effects emanating from the IKZF1 locus
Systemic lupus erythematosus SNP rs4917014 and unlinked mean corpuscular volume SNP
rs4917014 both affect expression of IKZF1 in cis. rs12718597 affects 50 trans-genes
(mostly involved in hemoglobin metabolism) while rs4917014 affects eight different genes
in trans: the rs4917014*T risk allele increases expression of genes involved in type I
interferon response. At a somewhat lower significance threshold of FDR 0.28 rs4917014*T
decreases complement C1QB expression. Both processes are hallmark features of SLE.
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Figure 3. Cholesterol SNP rs174546 affects LDLR in trans
The rs174546*T allele is known to be associated with a decrease in serum LDL cholesterol
and triglycerides levels. It increases the expression levels of three genes in cis, but also
increases gene expression levels of LDLR that encodes the LDL receptor.
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Figure 4. For 21 complex traits, pairs of unlinked trait-associated SNPs affect the same
downstream genes
We observed that for 21 different traits, there were pairs of unlinked SNPs that have
previously been reported to be associated with these traits and which also affect exactly the
same downstream genes in trans, whereas this is rarely observed when using an equally
sized, but permuted list of trans-eQTLs.
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Figure 5. Two unlinked type-1 diabetes risk alleles both increase STAT1 and GBP4 expression
rs3184504*T, a risk allele for type 1 diabetes (chromosome 12), affects the expression of
SH2B3 in cis, but also affects the expression levels of fourteen unique genes in trans,
including two interferon-γ response genes GBP4 and STAT1. Another unlinked type-1
diabetes risk allele (rs4788084*C on chromosome 16) also increases expression levels of
these two interferon-γ response genes, indicating that an elevated interferon-γ response is
important in type 1 diabetes.
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Table 1
Results of the cis- and trans-eQTL mapping analyses.
Summary statistics Cis-eQTLs Trans-eQTLs
Number of SNPs tested that pass QC 1,962,237 4,542 (of which 2,082 are associated with complex traits at genome-wide
significance, P < 5 × 10−8)
Number of probes tested that pass QC 29,891 34,061
Number of genes tested 14,542 16,332
Number of probes not mapping to genes 9,260 18,018
Number of statistical tests performed 11,172,453 153,134,630
Significance thresholds Cis-eQTLs Trans-eQTLs
Meta-analysis z-score Meta-analysis p-value Meta-analysis z-score Meta-analysis p-value
FDR < 0.05 significance 3.824 1.31 × 10−4 5.022 5.12 × 10−7
Bonferroni significance 5.867 4.5 × 10−9 6.287 3.3 × 10−10
cis-eQTL analysis FDR < 0.05 significance Bonferroni significance
Number of significant unique SNP-Probe pairs 664,097 395,543
Number of significant unique eQTL SNPs 397,310 266,036
Number of significant unique eQTL probes 8,228 5,738
Number of significant unique eQTL genes 6,418 4,690
Number of significant unique eQTL probes not mapping to genes 636 326
trans-eQTL analysis FDR < 0.05 significance Bonferroni significance
Number of significant unique SNP-Probe pairs 1,513 643
Number of significant unique eQTL SNPs 346 200
Number of significant unique eQTL probes 494 240
Number of significant unique eQTL genes 430 223
Number of significant unique eQTL probes not mapping to genes 35 13
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